ArticleFrontiers in oncology2025
Prognostic significance of pretherapeutic body mass index in surgically treated oral squamous cell carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Additional prognostic factors in patients with early-stage oral squamous cell carcinoma (OSCC) may optimize disease staging by identifying patients with high-risk constellations and facilitating risk-stratified therapies that lead to improved treatment outcome. Body mass index (BMI) is an established tool that is routinely recorded in everyday clinical practice and has demonstrated prognostic relevance in various other diseases. However, sufficient evidence regarding its impact in OSCC is lacking. The aim of this study is to evaluate the prognostic significance of pretherapeutic BMI in surgically treated OSCC patients. Materials and methods: This retrospective analysis included all patients with primary OSCC who underwent surgical therapy with or without the need for adjuvant therapy at Charité - Universitätsmedizin Berlin over a seven-year period. BMI was categorized based on the World Health Organization classification and correlated with clinical outcome. Overall survival (OS) and recurrence-free survival (RFS) were examined using Kaplan-Meier curves, Cox regression analysis, and log-rank test. The hazard ratios (HR) are presented together with 95% confidence intervals (CI). Results: A total of 394 patients (male: 257 (65.2%), female: 137 (34.8%)) with a mean age of 60.0 years were included. Of these, 25 (6.3%) met the criteria for underweight, 195 (49.2%) for normal weight, 121 (30.6%) for overweight and 55 (13.9%) for obesity. Underweight patients showed a significantly lower mean OS of 46.0 months (CI: 30.9-61.2 months) and RFS of 36.5 months (CI: 24.4-48.6 months) compared to all other BMI categories. In the multivariate Cox regression for OS, a reduced risk was observed for both normal-weight (HR: 0.32 CI: 0.11-0.90, p=0.031) and overweight patients (HR: 0.17 CI: 0.05-0.59, p=0.005) relative to those who were underweight. Regarding RFS, overweight patients demonstrated a significantly reduced risk compared to underweight individuals (HR: 0.28 CI: 0.09-0.89, p=0.031). Conclusion: Our results underscore the prognostic significance of pretherapeutic BMI as an independent risk factor in OSCC, particularly highlighting the need for intensified preoperative management in underweight patients due to their compromised outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.